"Kazakhstan Pharmaceuticals & Healthcare Report Q4 2014" Published

Kazakhstan's healthcare sector suffers from a lack of trained medical professionals and the inher en t difficulties of providing infrastructure and access to healthcare in such a large country. However, the government continues to show its commitment to improving healthcare as it allocates more funds to constructing new health clinics across the country. Although Kazakhstan's growing pharmaceutical industry will be driven by demand for generic medicines over the medium term, we believe that there are also significant opportunities for patented drug manufacturers as incomes rise and more advanced treatments become available.

Headline Expenditure Projections

* Pharmaceuticals: KZT273.92bn (USD1.80bn) in 2013 to KZT335.18bn (USD1.84bn) in 2014; up 22.4% in local currency terms and 2.3% in US dollar terms.
* Healthcare: KZT1,487.03bn (USD9.77bn) in 2013 to KZT1,712.78bn (USD9.41bn) in 2014; +15.3% in local currency terms and -3.7% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/878982_kazakhstan_pharmaceuticals_healthcare_report_q4.aspx?afid=302

Risk/Reward Rating: Kazakhstan has a RRR score of 47.3 out of 100, making it the 16th most attractive pharmaceutical market in Emerging Europe. Although the Kazakh market is characterised by relatively few market barriers and rapid growth, the industry's potential rewards are moderated by low per capita spending and an unfavourable rural-urban population split.

Key Trends And Developments

July

On July 4, the government of Kazakhstan amended the rules regarding the procurement of drugs. The amendments include rules on procurement of preventive drugs, medical devices and medical equipment. The pharmaceutical industry will provide a guaranteed volume of free medical care under the amended rules.

The Ministry of Education and Science (MES) of the Republic of Kazakhstan is planning to launch a project to build a biopharmaceutical plant, which will produce biologics in the Almaty region of Kazakhstan. The plant will have the capacity to produce up to 10mn doses per year. It will manufacture vaccines...

The Kazakhstan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kazakhstan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kazakhstani pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kazakhstan to test other views - a key input for successful budgeting and strategic business planning in the Kazakhstani pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
- Peru Pharmaceuticals & Healthcare Report Q4 2014